Harbour BioMed HBM9378 Phase I data: does long-acting TSLP inhibition change asthma treatment economics?
Harbour BioMed’s HBM9378 Phase I data shows long half-life and safety. Find out what this means for asthma, COPD, and TSLP competition.
Can NovelMed Therapeutics challenge established PNH drugs with its Bb-targeting antibody Ruxoprubart?
NovelMed Therapeutics advances Ruxoprubart for paroxysmal nocturnal hemoglobinuria with Phase II data and a new subcutaneous trial. Discover what comes next.
Why Precision Biologics is betting on tumor-specific neoepitopes to reshape monoclonal antibody cancer therapy
Precision Biologics highlights tumor-specific monoclonal antibodies at Festival of Biologics USA. Discover how neoepitope targeting could reshape cancer therapy.
Could Invivyd’s VYD2311 offer a safer alternative to mRNA COVID vaccines for vulnerable groups?
Invivyd’s LIBERTY trial could reshape COVID prophylaxis by comparing VYD2311 antibody safety with mRNA vaccines. See what’s at stake for regulators.
What Mirum’s Bluejay acquisition reveals about its long-term liver disease strategy
Mirum adds brelovitug in HDV through Bluejay deal. See how this could redefine rare liver disease leadership ahead of AZURE Phase 3 results in 2026.
How Brazil’s GMP approval for pembrolizumab biosimilar changes global biosimilar dynamics
Blau Farmacêutica’s pembrolizumab biosimilar earns ANVISA GMP approval—see what this means for Brazil’s global position in cancer immunotherapy.
What Rakuten Medical’s deal with LOTTE Biologics signals for photoimmunotherapy scale-up
Rakuten Medical taps LOTTE Biologics for global supply of its Alluminox cancer platform. Find out what this deal means for photoimmunotherapy’s future.
Sanofi’s tau-focused Alzheimer’s deal highlights growing confidence in non-amyloid targets
Sanofi’s $1 billion Alzheimer’s deal with ADEL highlights why tau biology is back in focus and what risks still stand between promise and proof.